Biomarkers.

Area of Science:

• Clinical diagnostics
• Biomarker assay validation
• Alzheimer's disease research

Background:

• Clinical Laboratory Improvement Amendments (CLIA) are vital for regulating laboratory testing accuracy and reliability.
• Alzheimer's disease (AD) biomarkers are crucial for early detection, diagnosis, and treatment, requiring CLIA approval for clinical integration.
• The Fujirebio Lumipulse amyloid-beta (AB) 42:40 cerebral spinal fluid (CSF) assay recently received FDA approval, necessitating CLIA certification for clinical use.

Purpose of the Study:

• To detail the process and requirements for obtaining Clinical Laboratory Improvement Amendments (CLIA) approval for Alzheimer's disease (AD) biomarkers.
• To explain the specific steps and validation needed for the Fujirebio Lumipulse AB 42:40 CSF assay to meet CLIA certification standards.
• To demonstrate the successful attainment of CLIA certification for a novel AD biomarker assay.

Main Methods:

• Reviewed Clinical Laboratory Improvement Amendments (CLIA) processes for Alzheimer's disease (AD) biomarkers.
• Executed validation protocols for the AB 42:40 ratio in CSF using the Lumipulse G1200 analyzer.
• Ensured compliance with CLIA staffing, monitoring, and documentation for a Certificate of Compliance, using biobank CSF across two laboratory settings for blinded technician assessment.

Main Results:

• Achieved Clinical Laboratory Improvement Amendments (CLIA) certification for the Fujirebio AD biomarker test by meeting accuracy, reproducibility, and clinical utility requirements.
• Demonstrated high correlation (R2=0.9819) in validation testing between two distinct laboratory sites, confirming test reliability.
• Successfully met all criteria for CLIA certification, paving the way for clinical integration of the AB 42:40 CSF assay.

Conclusions:

• CLIA certification enables the return of Fujirebio Lumipulse AB 42:40 biomarker results for clinical diagnosis and research in Alzheimer's disease (AD).
• CLIA approval confirms consistent performance of biomarker assays across clinical settings and patient populations, validating the Fujirebio CSF AB42:40 test.
• Clinical Laboratory Improvement Amendments (CLIA) approval is essential for making AD biomarkers accessible for routine clinical application, precision medicine, and early intervention strategies.